Showing 1 - 6 results of 6 for search 'Mayur Narkhede', query time: 0.03s Refine Results
  1. 1
    Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States

    Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United S... by Gaurav Goyal, Tylan Magnusson, Xiaoliang Wang, James Roose, Mayur Narkhede, Erlene Seymour

    Published 2022-12-01
    Get full text
    Article
  2. 2
    A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)

    A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL... by Mayur Narkhede, Nancy L. Bartlett, Sami Ibrahimi, Leslie Popplewell, Anna Seto, Jamie Bates, Yeonju Lee, Vaishnavi Ganti, Ling Han, Tianling Chen, Manish R. Patel

    Published 2023-05-01
    Get full text
    Article
  3. 3
    Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma

    Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma by Mayur Narkhede, Sarah Tomassetti, Madiha Iqbal, Antony Tin, Samuel Rivero-Hinojosa, Giby V. George, Hayley Widden, Ryan Benrud, Meenakshi Malhotra, Angel Rodriguez, Minetta C. Liu

    Published 2024-07-01
    Get full text
    Article
  4. 4
    Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.

    Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. by Surbhi Sidana, Mayur Narkhede, Paul Elson, Debbie Hastings, Beth Faiman, Jason Valent, Christy Samaras, Kimberly Hamilton, Hien K Liu, Mitchell R Smith, Frederic J Reu

    Published 2017-01-01
    Get full text
    Article
  5. 5
    Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.

    Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study. by Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, Weimin Liu, Regina M Stoltz, Allisa K Oman, Lucinda A Hall, Ran Li, Sarah Sterrett, Ellen R Frederick, Jeffrey R Lancaster, Mayur Narkhede, Amitkumar Mehta, Foluso J Ogunsile, Rima B Patel, Thomas J Ketas, Victor M Cruz Portillo, Albert Cupo, Benjamin M Larimer, Anju Bansal, Paul A Goepfert, Beatrice H Hahn, Randall S Davis

    Published 2023-06-01
    Get full text
    Article
  6. 6
    Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

    Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers by Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha, Ning Dong, David Qualls, Behzad Amoozgar, Brad Kahl, John Baird, Pavan Challa, Scott F Huntington, Jennifer Santos, Steven Bair, Mayur Narkhede, Shuning Li, Zachary Frosch, Carrie Ho, Stephen D Smith, Allison Winter, Daniel Landsburg, Fateeha Furqan, Mehdi Hamadani, Katelin Baird, Jason Romancik, Hanan Alharthy, Jennie Law, Leyla Bojanini, Ranjana Advani, Boyu Hu, Patrick Connor Johnson, Natalie S. Grover, Mwanasha Merril, Jennifer L. Crombie, Nazila Shafagati, Cole Sterling, Loretta J. Nastoupil, Narendranath Epperla, Emily C Ayers

    Published 2024-11-01
    Get full text
    Article

Search Tools: